Patents by Inventor Maximiliane Koenig

Maximiliane Koenig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220049020
    Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: April 6, 2021
    Publication date: February 17, 2022
    Inventors: Joerg Thomas REGULA, Stefan SEEBER, Wolfgang SCHAEFER, Sabine IMHOF-JUNG, Michael MOLHOJ, Maximiliane KOENIG, Peter BRUENKER, Christian KLEIN
  • Publication number: 20220041747
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Patent number: 11214622
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: January 4, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Patent number: 11180571
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 23, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
  • Publication number: 20210041163
    Abstract: Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index) and at positions 180-97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.
    Type: Application
    Filed: July 27, 2020
    Publication date: February 11, 2021
    Inventors: Hubert KETTENBERG, Maximiliane KOENIG, Tilman SCHLOTHAUER, Pernille FOGED JENSEN, Kasper RAND
  • Publication number: 20200190212
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Publication number: 20200103413
    Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.
    Type: Application
    Filed: May 20, 2019
    Publication date: April 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
  • Publication number: 20190062453
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 6, 2018
    Publication date: February 28, 2019
    Applicant: Roche Glycart AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
  • Patent number: 9926379
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: March 27, 2018
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Publication number: 20170211876
    Abstract: Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index), and at positions 180-97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.
    Type: Application
    Filed: June 10, 2015
    Publication date: July 27, 2017
    Inventors: Hubert KETTENBERGER, Maximiliane KOENIG, Tilman SCHLOTHAUER, Pernille FOGED JENSEN, Kasper RAND
  • Patent number: 9714292
    Abstract: The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 25, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Jens Fischer, Hubert Kettenberger, Maximiliane Koenig, Stefan Lorenz, Joerg Moelleken
  • Publication number: 20170145116
    Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 25, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG THOMAS REGULA, STEFAN SEEBER, WOLFGANG SCHAEFER, SABINE IMHOF-JUNG, MICHAEL MOLHOJ, MAXIMILIANE KOENIG, PETER BRUENKER, CHRISTIAN KLEIN
  • Publication number: 20170115304
    Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.
    Type: Application
    Filed: September 28, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
  • Publication number: 20140370019
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: December 18, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser